Osteoporosis | Topic engagement | Quality standard | |
Delgocitinib for treating moderate to severe chronic hand eczema [ID6408] | Draft guidance | Technology appraisal guidance | |
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256] | Draft guidance | Technology appraisal guidance | |
Leadless cardiac pacemaker implantation for bradyarrhythmias | Interventional procedure consultation | Interventional procedures guidance | |
Low energy contact X-ray brachytherapy for rectal cancer | Interventional procedure consultation | Interventional procedures guidance | |
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394] | Draft guidance | Technology appraisal guidance | |
Teprotumumab for treating thyroid eye disease [ID6432] | Draft guidance | Technology appraisal guidance | |
Suspected sepsis: recognition, diagnosis and early management | Draft guidance consultation | NICE guideline | |
Pegzilarginase for treating arginase-1 deficiency [ID4029] | Draft guidance | Highly specialised technology | |
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211] | Draft guidance | Technology appraisal guidance | |